Literature DB >> 31365365

Primary Fascial Closure During Laparoscopic Ventral Hernia Repair Improves Patient Quality of Life: A Multicenter, Blinded Randomized Controlled Trial.

Karla Bernardi1,2, Oscar A Olavarria1,2, Julie L Holihan1,2, Lillian S Kao1,2, Tien C Ko1, John S Roth3, Shawn Tsuda4, Khashayar Vaziri5, Mike K Liang1,2.   

Abstract

BACKGROUND: Observational studies have reported conflicting results with primary fascial closure (PFC) versus bridged repair during laparoscopic ventral hernia repair (LVHR).
OBJECTIVE: The aim of the study was to determine whether when evaluated in a randomized controlled trial (RCT), PFC compared to bridged repair would improve patient quality of life (QoL).
METHODS: In this blinded, multicenter RCT, patients scheduled for elective LVHR (hernia defects 3 to 10 cm on computed tomography scan) were randomized to PFC versus bridged repair. Primary outcome was change in QoL after LVHR using a validated, hernia-specific survey (1 = poor QoL and 100 = perfect QoL) that measures pain, function, cosmesis, and satisfaction. Secondary outcomes were postoperative surgical site occurrences (including hematoma, seroma, surgical site infection, and wound dehiscence), abdominal eventration, and hernia recurrence. The trial was powered to detect a difference in change in QoL of 7 points between the study groups. Outcomes were compared with Mann-Whitney U test or chi-square.
RESULTS: A total of 129 patients underwent LVHR and 107 (83%) completed follow-up at 2 years. Patients from both groups were similar at baseline. On median follow-up of 24 months (range: 9-42), patients treated with LVHR-PFC had on average a 12-point higher improvement in QoL compared to bridged repair (improvement in QoL, 41.3 ± 31.5 vs 29.7 ± 28.7, P value = 0.047). There were no differences in surgical site occurrence, eventration, or hernia recurrence between groups.
CONCLUSIONS: Among patients undergoing elective LVHR, the fascial defect should be closed. This is the first RCT demonstrating that PFC with LVHR significantly improves patient QoL. TRIAL REGISTRATION: This trial was registered with clinicaltrials.gov (NCT02363790).

Entities:  

Mesh:

Year:  2020        PMID: 31365365     DOI: 10.1097/SLA.0000000000003505

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  8 in total

1.  What is the reality in epigastric hernia repair?-a trend analysis from the Herniamed Registry.

Authors:  F Köckerling; D Adolf; K Zarras; R Fortelny; R Lorenz; B Lammers; W Reinpold; B Stechemesser; C Schug-Pass; D Weyhe
Journal:  Hernia       Date:  2021-04-10       Impact factor: 4.739

2.  Primary closure of the midline abdominal wall defect during laparoscopic ventral hernia repair: analysis of risk factors for failure and outcomes at 5 years follow-up.

Authors:  Julio Gómez-Menchero; Andrea Balla; Ana Fernández Carazo; Salvador Morales-Conde
Journal:  Surg Endosc       Date:  2022-06-21       Impact factor: 4.584

3.  A scoring system for predicting malignancy in intraductal papillary mucinous neoplasms of the pancreas: a multicenter EUROPEAN validation.

Authors:  Alba Manuel-Vázquez; Anita Balakrishnan; Paul Agami; Bodil Andersson; Frederik Berrevoet; Marc G Besselink; Ugo Boggi; Damiano Caputo; Alberto Carabias; Lucia Carrion-Alvarez; Carmen Cepeda Franco; Alessandro Coppola; Bobby V M Dasari; Sherley Diaz-Mercedes; Michail Feretis; Constantino Fondevila; Giuseppe Kito Fusai; Giuseppe Garcea; Victor Gonzabay; Miguel Ángel Gómez Bravo; Myrte Gorris; Bart Hendrikx; Camila Hidalgo-Salinas; Prashant Kadam; Dimitrios Karavias; Emanuele Kauffmann; Amar Kourdouli; Vincenzo La Vaccara; Stijn van Laarhoven; James Leighton; Mike S L Liem; Nikolaos Machairas; Dimitris Magouliotis; Adel Mahmoud; Marco V Marino; Marco Massani; Paola Melgar Requena; Keno Mentor; Niccolò Napoli; Jorieke H T Nijhuis; Andrej Nikov; Cristina Nistri; Victor Nunes; Eduardo Ortiz Ruiz; Sanjay Pandanaboyana; Baltasar Pérez Saborido; Radek Pohnán; Mariuca Popa; Belinda Sánchez Pérez; Francisco Sánchez Bueno; Alejandro Serrablo; Mario Serradilla-Martín; James R A Skipworth; Kjetil Soreide; Dimitris Symeonidis; Dimitris Zacharoulis; Piotr Zelga; Daniel Aliseda; María Jesús Castro Santiago; Carlos Fernández Mancilla; Raquel Latorre Fragua; Daniel Llwyd Hughes; Carmen Payá Llorente; Mickaël Lesurtel; Tom Gallagher; José Manuel Ramia
Journal:  Langenbecks Arch Surg       Date:  2022-10-06       Impact factor: 2.895

4.  Synthetic versus Biologic Mesh for Complex Open Ventral Hernia Repair: A Pilot Randomized Controlled Trial.

Authors:  Oscar A Olavarria; Karla Bernardi; Naila H Dhanani; Nicole B Lyons; John A Harvin; Stefanos G Millas; Tien C Ko; Lillian S Kao; Mike K Liang
Journal:  Surg Infect (Larchmt)       Date:  2020-12-01       Impact factor: 1.853

5.  Robotic versus laparoscopic ventral hernia repair: multicenter, blinded randomized controlled trial.

Authors:  Oscar A Olavarria; Karla Bernardi; Shinil K Shah; Todd D Wilson; Shuyan Wei; Claudia Pedroza; Elenir B Avritscher; Michele M Loor; Tien C Ko; Lillian S Kao; Mike K Liang
Journal:  BMJ       Date:  2020-07-14

6.  Ventralex® ST Patch for Laparoscopic Repair of Ventral Hernias.

Authors:  Razvan Catalin Popescu; Florin Botea; Cristina Dan; Ionut-Eduard Iordache; Andrei Ghioldis; Nicoleta Leopa
Journal:  JSLS       Date:  2021 Oct-Dec       Impact factor: 2.172

7.  A prospective, multicenter trial of a long-term bioabsorbable mesh with Sepra technology in cohort of challenging laparoscopic ventral or incisional hernia repairs (ATLAS trial).

Authors:  William W Hope; Adel G El-Ghazzawy; Brad A Winterstein; Jeffrey A Blatnik; S Scott Davis; Jacob A Greenberg; Noel C Sanchez; Eric M Pauli; Daniel M Tseng; Karl A LeBlanc; Kurt E Roberts; Curtis E Bower; Eduardo Parra-Davila; J Scott Roth; Corey R Deeken; Eric F Smith
Journal:  Ann Med Surg (Lond)       Date:  2021-12-06

8.  Laparoscopic ventral and incisional hernia repair using intraperitoneal onlay mesh with peritoneal bridging.

Authors:  F Ali; G Sandblom; A Wikner; G Wallin
Journal:  Hernia       Date:  2021-09-24       Impact factor: 4.739

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.